american heart association glp-1 Barriers to RAs GLP-1 receptor agonists (GLP-1RAs): cardiovascular

Clinically tested results include: Average weight loss of 28 lbs in just 10 weeks 6.7 inches off the waist 27% reduction in LDL cholesterol Up to 50% decrease in metabolic syndrome

Cagrilintide and Retatrutide target different but complementary pathways within metabolism, which together makes them interesting within research: Cagrilintide mainly focuses on satiety and being full faster Retatrutide is being investigated for its broad effects on energy consumption and metabolic processes In combined research settings, we look at how: Saturation (Cagrilintide) and metabolic activation (Retatrutide) can complement each other within a single hormonal approach

With expert oversight and custom protocols, Audra Foster, N.D

With the decrease of hyperinsulinemia, PDA stroma is thinner (Zhang et al., 2019)